231 related articles for article (PubMed ID: 25956741)
1. Inhibition of the ERCC1-XPF structure-specific endonuclease to overcome cancer chemoresistance.
McNeil EM; Astell KR; Ritchie AM; Shave S; Houston DR; Bakrania P; Jones HM; Khurana P; Wallace C; Chapman T; Wear MA; Walkinshaw MD; Saxty B; Melton DW
DNA Repair (Amst); 2015 Jul; 31():19-28. PubMed ID: 25956741
[TBL] [Abstract][Full Text] [Related]
2. Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells.
Arora S; Heyza J; Zhang H; Kalman-Maltese V; Tillison K; Floyd AM; Chalfin EM; Bepler G; Patrick SM
Oncotarget; 2016 Nov; 7(46):75104-75117. PubMed ID: 27650543
[TBL] [Abstract][Full Text] [Related]
3. Targeting the DNA Repair Endonuclease ERCC1-XPF with Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCG) and Its Prodrug to Enhance Cisplatin Efficacy in Human Cancer Cells.
Heyza JR; Arora S; Zhang H; Conner KL; Lei W; Floyd AM; Deshmukh RR; Sarver J; Trabbic CJ; Erhardt P; Chan TH; Dou QP; Patrick SM
Nutrients; 2018 Nov; 10(11):. PubMed ID: 30400270
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.
Arora S; Kothandapani A; Tillison K; Kalman-Maltese V; Patrick SM
DNA Repair (Amst); 2010 Jul; 9(7):745-53. PubMed ID: 20418188
[TBL] [Abstract][Full Text] [Related]
5. DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy.
McNeil EM; Melton DW
Nucleic Acids Res; 2012 Nov; 40(20):9990-10004. PubMed ID: 22941649
[TBL] [Abstract][Full Text] [Related]
6. Computational Characterization of Small Molecules Binding to the Human XPF Active Site and Virtual Screening to Identify Potential New DNA Repair Inhibitors Targeting the ERCC1-XPF Endonuclease.
Gentile F; Barakat KH; Tuszynski JA
Int J Mol Sci; 2018 Apr; 19(5):. PubMed ID: 29710850
[TBL] [Abstract][Full Text] [Related]
7. Computer-aided drug design of small molecule inhibitors of the ERCC1-XPF protein-protein interaction.
Gentile F; Elmenoufy AH; Ciniero G; Jay D; Karimi-Busheri F; Barakat KH; Weinfeld M; West FG; Tuszynski JA
Chem Biol Drug Des; 2020 Apr; 95(4):460-471. PubMed ID: 31891209
[TBL] [Abstract][Full Text] [Related]
8. Catechols and 3-hydroxypyridones as inhibitors of the DNA repair complex ERCC1-XPF.
Chapman TM; Gillen KJ; Wallace C; Lee MT; Bakrania P; Khurana P; Coombs PJ; Stennett L; Fox S; Bureau EA; Brownlees J; Melton DW; Saxty B
Bioorg Med Chem Lett; 2015 Oct; 25(19):4097-103. PubMed ID: 26318993
[TBL] [Abstract][Full Text] [Related]
9. Functional and physical interactions between ERCC1 and MSH2 complexes for resistance to cis-diamminedichloroplatinum(II) in mammalian cells.
Lan L; Hayashi T; Rabeya RM; Nakajima S; Kanno Si; Takao M; Matsunaga T; Yoshino M; Ichikawa M; Riele Ht; Tsuchiya S; Tanaka K; Yasui A
DNA Repair (Amst); 2004 Feb; 3(2):135-43. PubMed ID: 14706347
[TBL] [Abstract][Full Text] [Related]
10. Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs.
Kirschner K; Melton DW
Anticancer Res; 2010 Sep; 30(9):3223-32. PubMed ID: 20944091
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance.
Li W; Melton DW
Oncogene; 2012 May; 31(19):2412-22. PubMed ID: 21996734
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression.
Usanova S; Piée-Staffa A; Sied U; Thomale J; Schneider A; Kaina B; Köberle B
Mol Cancer; 2010 Sep; 9():248. PubMed ID: 20846399
[TBL] [Abstract][Full Text] [Related]
13. Targeting DNA Repair in Tumor Cells via Inhibition of ERCC1-XPF.
Elmenoufy AH; Gentile F; Jay D; Karimi-Busheri F; Yang X; Soueidan OM; Weilbeer C; Mani RS; Barakat KH; Tuszynski JA; Weinfeld M; West FG
J Med Chem; 2019 Sep; 62(17):7684-7696. PubMed ID: 31369707
[TBL] [Abstract][Full Text] [Related]
14. XPF knockout via CRISPR/Cas9 reveals that ERCC1 is retained in the cytoplasm without its heterodimer partner XPF.
Lehmann J; Seebode C; Smolorz S; Schubert S; Emmert S
Cell Mol Life Sci; 2017 Jun; 74(11):2081-2094. PubMed ID: 28130555
[TBL] [Abstract][Full Text] [Related]
15. Acetylation of XPF by TIP60 facilitates XPF-ERCC1 complex assembly and activation.
Wang J; He H; Chen B; Jiang G; Cao L; Jiang H; Zhang G; Chen J; Huang J; Yang B; Zhou C; Liu T
Nat Commun; 2020 Feb; 11(1):786. PubMed ID: 32034146
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and in vitro cell-free/cell-based biological evaluations of novel ERCC1-XPF inhibitors targeting DNA repair pathway.
Elmenoufy AH; Gentile F; Jay D; Karimi-Busheri F; Yang X; Soueidan OM; Mani RS; Ciniero G; Tuszynski JA; Weinfeld M; West FG
Eur J Med Chem; 2020 Oct; 204():112658. PubMed ID: 32738410
[TBL] [Abstract][Full Text] [Related]
17. Crystal structure and DNA binding functions of ERCC1, a subunit of the DNA structure-specific endonuclease XPF-ERCC1.
Tsodikov OV; Enzlin JH; Schärer OD; Ellenberger T
Proc Natl Acad Sci U S A; 2005 Aug; 102(32):11236-41. PubMed ID: 16076955
[TBL] [Abstract][Full Text] [Related]
18. Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin.
De Silva IU; McHugh PJ; Clingen PH; Hartley JA
Nucleic Acids Res; 2002 Sep; 30(17):3848-56. PubMed ID: 12202770
[TBL] [Abstract][Full Text] [Related]
19. Interstrand crosslink repair: can XPF-ERCC1 be let off the hook?
Bergstralh DT; Sekelsky J
Trends Genet; 2008 Feb; 24(2):70-6. PubMed ID: 18192062
[TBL] [Abstract][Full Text] [Related]
20. Domain mapping of the DNA binding, endonuclease, and ERCC1 binding properties of the human DNA repair protein XPF.
McCutchen-Maloney SL; Giannecchini CA; Hwang MH; Thelen MP
Biochemistry; 1999 Jul; 38(29):9417-25. PubMed ID: 10413517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
